Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (JAGX) announces agreement with FDA for a clinical field study of Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs. The drug received conditional approval in December 2021 and is the first of its kind. The study aims for full approval by collecting evidence of effectiveness. Canalevia-CA1 helps dogs undergoing chemotherapy by improving comfort and quality of life.
The agreement between Jaguar Health and the FDA on the clinical field study design for Canalevia-CA1 represents a significant milestone in the drug's regulatory pathway. The conditional approval status granted by the FDA in December 2021 indicates that the drug has met preliminary safety and efficacy standards, which allows for its commercialization while further evidence is gathered. The full approval process is critical as it will likely increase the credibility and market potential of Canalevia-CA1, as veterinarians and pet owners often prefer treatments with full regulatory endorsement.
From a market perspective, the potential for FDA grants could alleviate some of Jaguar Health's financial burden associated with the clinical study. This could improve the company's fiscal health and possibly influence investor sentiment. The drug's unique position as the first and only FDA-approved treatment for CID in dogs could provide Jaguar Health with a competitive edge in the veterinary pharmaceuticals market, potentially leading to increased market share and revenue.
However, it's important to monitor the progress of the clinical field study, as any setbacks or negative results could impact the company's stock performance. The veterinary pharmaceutical market is also subject to stringent regulations and any changes in regulatory standards could affect the approval timeline for Canalevia-CA1.
Reaching an agreement with the FDA is a key step for Jaguar Health, as it could lead to full approval and expanded marketing opportunities for Canalevia-CA1. The prescription-only status and its position as the sole FDA-approved drug for CID in dogs suggest a targeted niche market, which could translate into a stable revenue stream. The company's ability to secure a grant from the FDA would be an indicator of cost-effective management of the approval process.
Investors should consider the potential market size for Canalevia-CA1, factoring in the prevalence of chemotherapy treatments in dogs and the demand for supportive care products. The financial implications of achieving full approval are substantial, as it could lead to increased sales and partnerships with veterinary distributors, further solidifying Jaguar Health's market position.
It is also essential to evaluate Jaguar Health's operational capacity to meet potential demand and manage the supply chain for the sustainably harvested crofelemer. Any disruptions could adversely affect production and distribution, impacting the company's financial performance and stock valuation.
The veterinary healthcare market is growing, driven by increased pet ownership and a greater focus on pet well-being. Canalevia-CA1's positioning as a unique treatment for CID in dogs taps into this expanding market. The drug's conditional approval and the pursuit of full approval suggest a strategic move to solidify its presence in the market ahead of potential competitors.
Understanding the demographics of pet owners who opt for chemotherapy for their dogs and their willingness to invest in supportive treatments like Canalevia-CA1 is crucial for projecting market potential. Additionally, the partnership with leading veterinary distributors is a strategic asset that could facilitate rapid market penetration post-full approval.
Long-term success for Canalevia-CA1 will depend on the outcomes of the clinical field study, the drug's efficacy and safety profile and Jaguar Health's marketing strategy. The company's ability to communicate the benefits of Canalevia-CA1 to veterinarians and pet owners will be vital for adoption and sales growth.
02/15/2024 - 08:30 AM
Canalevia® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA
By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree
SAN FRANCISCO, CA / ACCESSWIRE / February 15, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) , under its Jaguar Animal Health tradename for the veterinary market, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design and conduct of a clinical field study of Canalevia-CA1 (crofelemer delayed-release tablets), the company's FDA conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, for full approval of the product.
Canalevia-CA1 received conditional approval in December 2021 from the FDA for the treatment of CID in dogs and is available from multiple leading veterinary distributors in the U.S. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval.
"We are thrilled that we have reached concurrence with the FDA on Jaguar's protocol for our planned clinical field study of Canalevia-CA1," said Michael Guy, DVM, MS, PhD, Jaguar Health's Vice President of Preclinical and Nonclinical Studies. "This milestone is an important step forward on the pathway toward full approval for Canalevia-CA1. Canalevia-CA1 is an important prescription drug for the veterinary community and the thousands of dogs experiencing CID. Canalevia-CA1 can help support the comfort and quality of life of dogs while being treated with chemotherapy, which may help keep them compliant with their life-saving treatment. Receipt of concurrence from the FDA on this protocol has the additional benefit of allowing us to apply for a grant from the FDA to help defer a portion of the costs to run the planned clinical field study."
Canalevia-CA1 is referenced in an article about new therapies in veterinary oncology published January 6, 2024 in the journal Veterinary Clinics of North America: Small Animal Practice . The article is titled "New Therapies in Veterinary Oncology," and the article abstract can be accessed by clicking here
About Conditional Approval and Full Approval
FDA's conditional approval allows a drug company to legally sell the animal drug before proving it meets the "substantial evidence" standard of effectiveness for full approval. The company can also legally promote and advertise the conditionally approved drug for the labeled uses. The conditional approval is valid for one year. The drug company can ask FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from FDA, the company must show active progress toward proving "substantial evidence of effectiveness" for full approval. During the conditional approval period, the company can legally market the animal drug for the labeled uses while collecting the remaining effectiveness data. After collecting the necessary data, the company then applies to FDA for full approval. FDA reviews the application and, if appropriate, fully approves the drug.
About Chemotherapy-induced Diarrhea (CID) in Dogs
According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer.1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S.
Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.
Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID.
About Canalevia® -CA1
Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a "small number" threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.
About Crofelemer
Crofelemer is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Jaguar Health family company Napo Pharmaceuticals has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals' crofelemer drug product candidate is the subject of the OnTarget study, a pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit Jaguar on LinkedIn: https://www.linkedin.com/company/jaguar-health/
Visit Jaguar on X: https://twitter.com/Jaguar_Health
Visit Jaguar on Instagram: https://www.instagram.com/jaguarhealthcommunity/
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will apply for a grant from the FDA to help defer a portion of the costs to run the planned clinical field study for Canalevia-CA1. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1 "Cancer in Pets." American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets
2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398
CONTACT:
hello@jaguar.health
SOURCE: Jaguar Health, Inc.
press release on accesswire.com
What is the FDA conditionally approved treatment for CID in dogs by Jaguar Health, Inc.?
Canalevia-CA1, a canine-specific formulation of crofelemer, is the FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs by Jaguar Health, Inc.
What is Canalevia-CA1 and where is it sourced from?
Canalevia-CA1 is a prescription drug for dogs, formulated from crofelemer sustainably harvested from the Croton lechleri tree.
When did Canalevia-CA1 receive conditional approval from the FDA?
Canalevia-CA1 received conditional approval from the FDA in December 2021.
What is the purpose of the clinical field study agreement between Jaguar Health and the FDA?
The clinical field study agreement aims to collect evidence of effectiveness for Canalevia-CA1 to achieve full FDA approval.
How does Canalevia-CA1 benefit dogs undergoing chemotherapy?
Canalevia-CA1 helps improve the comfort and quality of life of dogs experiencing chemotherapy-induced diarrhea, supporting their compliance with life-saving treatment.
